Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis patients

References

• Van Eden W, Van der Zee R, Van Kooten P, Berlo SE, Cobelens PM, Kavelaars A, et al. Balancing the immune system: Th1 and Th2. Ann Rheum Dis 2002; 61(Suppl II)ii25–ii28
   PubMedGoogle Scholar
• Weiner HL, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, et al. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12: 809–837
   PubMed Web of Science ®Google Scholar
• Weiner HL. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 18: 335–343
   PubMedGoogle Scholar
• Toussirot E. Oral tolerance in the treatment of rheumatoid arthritis. Curr Drug Target Inflam Allergy 2002; 1: 45–52
   PubMedGoogle Scholar
• Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999; 48: 109–119
   Google Scholar
• Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 1727–1730
   PubMed Web of Science ®Google Scholar
• Trentham DE. Oral tolerization as treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 525–536
   PubMedGoogle Scholar
• Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996; 39: 41–51
   PubMedGoogle Scholar
• Barnett ML, Kremer JM, St Clair EW, O.Clegg D, Furst D, Weisman M, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998; 41: 290–297
   PubMed Web of Science ®Google Scholar
• Peters DH, Goa KL. OM-8980: An initial review of its pharmacology and therapeutic potential in rheumatoid arthritis. Clin Immunother 1994; 2: 65–77
   Google Scholar
• Wendling U, Bloemendal A, Van Der Zee R, Rutten VPMG, Van Kooten PJS, Farine JC, et al. Antirheumatic E.Coli extract OM-89 induces T cell responses to Hsp60 and 70. Int J Immunopharmacol 1997; 19: 565–568
   PubMedGoogle Scholar
• Young RA. Stress proteins and immunology. Annu Rev Immunol 1990; 8: 401–420
   PubMed Web of Science ®Google Scholar
• Van Eden W, Hogervorst EJM, Hensen EJ, Van Der Zee R, Van Embden JDA, Cohen IR. A cartilage-mimicking T-cell epitope on a 65 K mycobacterial heat-shock protein: Adjuvant arthritis as model for human rheumatoid arthritis. Curr Top Microbiol Immunol 1989; 145: 27–43
   PubMedGoogle Scholar
• Hogervorst EJM, Wagenaar JPA, Boog CJP, Van Der Zee, Van Embden JDA, Van Eden W. Ajuvant arthritis and immunity to the mycobacterial 65 kDa heat shock protein. Int Immunol 1992; 4: 719–727
   PubMed Web of Science ®Google Scholar
• Cobelens PM, Heijen CJ, Nieuwenhuis EES, Kramer PPG, Van Der Zee R, Van Eden W, et al. Treatment of adjuvant-induced arthritis by oral administration of mycobacterial Hsp65 during disease. Arthritis Rheum 2000; 43: 2694–2702
   PubMedGoogle Scholar
• Cobelens PM, Kavelaars A, Van Der Zee, Van Eden W, Heijen CJ. Dynamics of mycobacterial HSP65 induced T-cell cytokine expression during oral tolerance induction in adjuvant arthritis. Rheumatology 2002; 41: 775–779
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane D, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324
   PubMed Web of Science ®Google Scholar
• Farine JC, Meredith M. Subreum (OM-8980) and rheumatoid arthritis. A novel immunomodulating drug from natural product developments. Advances in Anti-Rheumatic Therapy, KD Rainsford. CRC Press, Boca Raton 1996; 167–180
   Google Scholar
• Sharrock CEM, Kamiski E, Man S. Limiting dilution analysis of human T cells: A useful clinical tool. Immunol Today 1990; 11: 281–286
   PubMedGoogle Scholar
• Brackertz D, Vischer TL. OM-8980 in rheumatoid arthritis: A six-month double blind placebo controlled multicentre study. J Rheumatol 1989; 16: 19–23
   PubMed Web of Science ®Google Scholar
• Willis D, Moore AR, Gowland G, Willoughby DA. Polyarthritis in the rat: Effect of tolerance and sensitization to the bacterial extract OM-89 with a possible mode of action. Br J Rheumatol 1995; 34: 1135–1138
   PubMedGoogle Scholar
• Polla BS, Baladi S, Fuller K, Rook G. Presence of hsp65 in bacterial extracts (OM-89): A possible mediator of orally-induced tolerance?. Experientia 1995; 51: 775–779
   PubMedGoogle Scholar
• Bloemendal A, Van Der Zee R, Rutten VPMG, Van Kooten PJS, Farine JC, Van Eden W. Experimental immunization with anti-rheumatic bacterial extract OM-89 induces T cell responses to heat shock protein (hsp) 60 and hsp70; modulation of peripheral immunological tolerance as its possible mode of action in the treatment of rheumatoid arthritis (RA). Clin Exp Immunol 1997; 110: 72–78
   PubMedGoogle Scholar
• Kingston AE, Hicks CA, Colston MJ, Billingham ME. A 71 kD heat shock protein (hsp) from mycobacterium tuberculosis has modulatory effects on experimental rat arthritis. Clin Exp Immunol 1996; 103: 77–82
   PubMed Web of Science ®Google Scholar
• McGuirk P, Mills HGK. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002; 23: 450–455
   PubMed Web of Science ®Google Scholar
• Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer JP, Groux H. A comparative study between T regulatory Type 1 and CD4+CD25+T cells in the control of inflammation. J Immunol 2003; 171: 5018–5026
   PubMed Web of Science ®Google Scholar
• Phipps PA. Induction of Tr1 cells: A possible mechanism in the therapeutic action of OM-89. Inflamm Res 1999; 48(Suppl 2)S138–S139
   Google Scholar